Embattled J&J plant cited again by FDA

FDA inspectors aren't convinced that Johnson & Johnson ($JNJ) is doing enough to fix problems at its troubled Fort Washington, PA, plant. That's the facility that produced the children's drugs caught up in the massive recall earlier this year. Since then, it's been a major focus in J&J's efforts to fix its manufacturing slip-ups, which prompted more than a dozen recent recalls.

But in a recent visit to the McNeil Consumer Healthcare plant, which has been closed for an overhaul since April, FDA inspectors identified a number of quality control problems. The plant's staff didn't handle customer complaints properly, didn't fully review discrepancies in product batches and didn't keep proper records, the inspectors said.

The company says it's toiling to bring its processes up to snuff. In a statement, McNeil said it has been "working diligently to ensure that our manufacturing operations meet the level of quality that consumers and the FDA expect of us. While the company has made progress...this is an ongoing commitment."

Indeed. J&J has been reviewing its manufacturing and quality control companywide, a process that has resulted in a couple of new recalls in the last two months. A plant in Puerto Rico has been another focus of concern, as products made there turned up with a musty, moldy odor and had to be recalled. FDA inspectors have cited that plant for shortfalls as well.

- read the Reuters news

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.